Sanofi: positive data for esophagitis in children
(CercleFinance.com) - Sanofi reports that a Phase III trial demonstrated that the efficacy and safety profile of Dupixent, administered for one year to children aged one to 11 years with eosinophilic esophagitis, remained constant.
These positive results represent the first analysis of long-term data in this age group, and will be the subject of a late-breaking presentation on 25 October at the American College of Gastroenterology 2023 Scientific Meeting.
A supplemental Biologics License Application is currently under priority review in the US; if approved, Dupixent will be the first and only drug approved by the FDA for this disease in this category of children.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
These positive results represent the first analysis of long-term data in this age group, and will be the subject of a late-breaking presentation on 25 October at the American College of Gastroenterology 2023 Scientific Meeting.
A supplemental Biologics License Application is currently under priority review in the US; if approved, Dupixent will be the first and only drug approved by the FDA for this disease in this category of children.
Copyright (c) 2023 CercleFinance.com. All rights reserved.